Edition:
United States

Verona Pharma PLC (VRNA.OQ)

VRNA.OQ on NASDAQ Stock Exchange Global Market

14.55USD
23 Feb 2018
Change (% chg)

$1.90 (+15.02%)
Prev Close
$12.65
Open
$13.95
Day's High
$14.87
Day's Low
$13.95
Volume
1,429
Avg. Vol
1,256
52-wk High
$17.50
52-wk Low
$10.44

Latest Key Developments (Source: Significant Developments)

Verona Pharma Expects To Report Top-Line Data From Phase 2b Trial Of Nebulized RPl554​ Early In Q2
Tuesday, 13 Feb 2018 07:35am EST 

Feb 13 (Reuters) - Verona Pharma Plc ::VERONA PHARMA PROVIDES CLINICAL DEVELOPMENT UPDATE.VERONA PHARMA PLC - ‍ANTICIPATES REPORTING TOP-LINE DATA FROM ITS PHASE 2B TRIAL EARLY IN Q2 OF 2018 FOR NEBULIZED RPL554​.VERONA PHARMA PLC - ‍ANTICIPATES REPORTING TOP-LINE DATA FROM ITS PHASE 2A TRIAL IN LATE Q1 OF 2018 FOR CLINICAL TRIAL OF RPL554 FOR CYSTIC FIBROSIS​.  Full Article

Verona Pharma announces positive top-line data from Phase 2A clinical trial in COPD with RPL554 dosed in addition to Tiotropium
Thursday, 7 Sep 2017 02:00am EDT 

Sept 7 (Reuters) - VERONA PHARMA PLC ::ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 2A CLINICAL TRIAL IN COPD WITH RPL554 DOSED IN ADDITION TO TIOTROPIUM (SPIRIVA).  Full Article

Verona Pharma Plc's American Depositary Shares open at $13.50 in debut
Thursday, 27 Apr 2017 10:03am EDT 

April 27 (Reuters) - :Verona Pharma Plc's American Depositary Shares open at $13.50 in debut, flat from IPO price of $13.50 per ADS.  Full Article

Verona Pharma announces pricing of global offering, approval to list on NASDAQ
Wednesday, 26 Apr 2017 11:13pm EDT 

April 26 (Reuters) - Verona Pharma Plc :Verona Pharma announces pricing of global offering and approval to list on the NASDAQ global market.Pricing of its global offering comprising 5.7 million American Depositary Shares at a price of $13.50 per ADS.Pricing of global offering also comprising 1.2 million ordinary shares at a price of £1.32 per ordinary share.  Full Article

Verona Pharma Plc files for IPO of up to $86.3 million
Monday, 3 Apr 2017 05:39pm EDT 

Verona Pharma Plc : Verona Pharma Plc files for IPO of up to $86.3 million . Verona Pharma Plc says Jefferies, Stifel, Wedbush Pacgrow, and SunTrust Robinson Humphrey are underwriters to IPO .Verona Pharma Plc says it has applied to list its ads on NASDAQ under the symbol "VRNA".  Full Article

Verona Pharma plc reports positive results from RPL554 dose-finding study
Tuesday, 15 Mar 2016 03:00am EDT 

Verona Pharma plc:Says positive headline data from a Phase IIa dose-finding clinical study using the Company's new proprietary nebulised formulation of RPL554.RPL554 is a novel inhaled PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory properties in same molecule, currently in development as a nebulised treatment for acute exacerbations in chronic obstructive pulmonary disorder (COPD) patients in hospital or home-care setting.Says such patients typically require additional bronchodilation as well as anti-inflammatory treatment despite being on maximum doses of approved COPD medications (which often contain salbutamol).Says primary objective of study met.Nebulised RPL554 demonstrated a dose-dependent bronchodilator response in asthma patients; the response was highly statistically significant (p<0.0001) at all doses tested1.  Full Article

BRIEF-Verona Pharma Expects To Report Top-Line Data From Phase 2b Trial Of Nebulized RPl554​ Early In Q2

* VERONA PHARMA PLC - ‍ANTICIPATES REPORTING TOP-LINE DATA FROM ITS PHASE 2B TRIAL EARLY IN Q2 OF 2018 FOR NEBULIZED RPL554​